0000950170-24-002689.txt : 20240108 0000950170-24-002689.hdr.sgml : 20240108 20240108073007 ACCESSION NUMBER: 0000950170-24-002689 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35776 FILM NUMBER: 24518337 BUSINESS ADDRESS: STREET 1: 103 CARNEGIE CENTER STREET 2: SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-649-9272 MAIL ADDRESS: STREET 1: 103 CARNEGIE CENTER STREET 2: SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 8-K 1 acst-20240105.htm 8-K 8-K
false000144419200014441922024-01-052024-01-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 05, 2024

 

 

ACASTI PHARMA INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Quebec

001-35776

98-1359336

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

103 Carnegie Center

Suite 300

 

Princeton, New Jersey

 

08540

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 609 649-9272

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, no par value per share

 

ACST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately. Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer. Mr. Ford will continue serving the Company as a financial consultant on an as-needed basis.

 

Robert J. DelAversano, 52, is a certified public accountant and has over twenty-five years of experience in accounting including thirteen years in public accounting. Mr. DelAversano joined the Company in November 2023 as Vice President, Finance. From 2018 to July 2023, Mr. DelAversano worked in roles of increasing seniority at OncoSec Medical Incorporated (“OncoSec”), a clinical-stage immuno-oncology company, which positions included Vice President of Finance, Principal Accounting Officer and Controller, and Executive Director of Finance, where he had global responsibility for accounting, external financial reporting, and financial controls covering all aspects of OncoSec’s business. Prior to joining OncoSec, Mr. DelAversano was the Director of Financial Reporting and Taxation at Brio Financial Group (“Brio”), where he served as the firm’s Director of Financial Reporting and Taxation, consulting with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC and oversaw its accounting and tax practice with industry focuses in manufacturing, wholesalers and medical devices services. Mr. DelAversano received a B.S. in Accounting from Rider University.

 

In his position of Vice President, Finance, Mr. DelAversano is entitled to an annual base salary of $290,000 and has a target bonus opportunity of up to 30% of his base salary, payable upon the achievement of operational and financial targets established by the Board. In connection with his appointment to the position of Vice President, Finance, Mr. DelAversano was awarded stock options to purchase 42,000 common shares of the Company at an exercise price of $2.125 per share, which options vest in equal quarterly installments over a period of 36 months. Mr. DelAversano is eligible to participate in and receive additional equity awards under the Company's Stock Option Plan and Equity Incentive Plan. The foregoing description of Mr. DelAversano’s compensation does not purport to be complete and is qualified in its entirety by reference to the full text of Mr. DelAversano’s offer letter, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.

 

There were no changes to Mr. DelAversano’s compensation arrangements with the Company in connection with his appointment to the roles of principal financial officer and principal accounting officer of the Company.

 

There are no family relationships between Mr. DelAversano and any director or executive officer of the Company. There are no transactions between Mr. DelAversano and the Company that would require disclosure under Item 404(a) of Regulation S-K.

Item 9.01 Exhibits.

(d) Exhibits

 

Exhibit

 

Description

10.1

 

Offer Letter by and between Robert J. DelAversano and the Company, dated November 21, 2023.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ACASTI PHARMA INC.

 

 

 

 

Date:

January 8, 2024

By:

/s/ Prashant Kohli

 

 

 

Prashant Kohli
Chief Executive Officer

 


EX-10.1 2 acst-ex10_1.htm EX-10.1 EX-10.1

img95305537_0.jpg 

 

November 20, 2023

 

PRIVATE AND CONFIDENTIAL

DELIVERED BY EMAIL

 

Robert DelAversano

 

 

Dear Robert:

 

We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”):

 

Title: Vice President, Finance

 

Reporting to: Prashant Kohli, Chief Executive Officer

 

Base Salary: Annualized base salary of $290,000, less applicable deductions and withholdings.

 

Annual Bonus: You will be eligible to earn an annual discretionary bonus of up to 30 % of your base salary as determined by Acasti in its sole discretion. The bonus, if any, for the given year will be paid following the completion of such year. You must remain employed with Acasti throughout the year for which the bonus is paid, and up to and including the bonus payment date.

 

Stock Option: Subject to approval by the board of directors of the Company, you will be granted pursuant to Acasti’s equity incentive plan (the “Plan”), an option to purchase common shares in the capital of Acasti (the “Option”), with a price per share equal to the fair market value of a common share, as determined by the board of directors at the time of grant. The grant of the Option to you shall be conditional upon: (a) your continued employment with Acasti at the time of grant; (b) you entering into an option agreement with Acasti (the “Option Agreement”); and (c) any other terms and conditions set forth in the Plan, your Option Agreement and as may be determined by the board of directors in its sole discretion at the time of grant.

 

Benefits: Subject to the terms and conditions of the applicable benefit plans and policies, you will be eligible to participate in such group benefit plans as Acasti may make available in its sole discretion.

 

Vacation: Vacation entitlement, including treatment of unused vacation time, will be in accordance with Acasti’s vacation policy as in effect from time to time.

 



Page
2

Start Date: November 27, 2023

 

 

As a condition of employment with Acasti Pharma, you will be required to read, sign and return a copy of the enclosed Confidentiality of Information and Ownership of Proprietary Property Agreement. On your first day of employment, you will be required to provide original documents from the enclosed List of Acceptable Documents (I-9) which prove your identity and right to work in the United States.

 

The Company is hiring you as an at-will employee, which means that you have the right to terminate your employment with Acasti at any time, for any reason, with or without notice. Similarly, Acasti has the right to terminate the employment relationship at any time, for any reason, with or without notice. Any contrary representations, which may have been made to you, are superseded by this offer. Any modifications to this “at-will” term of your employment must be in writing and signed by you and Acasti’s CEO.

 

This offer expires five business days from the date of this letter. Please indicate your acceptance of our offer by signing and returning a copy of this letter to me as soon as possible.

 

On behalf of Acasti, we look forward to having you join us as we work together to advance science in support of better patient outcomes and to create value for the employees and shareholders of Acasti.

 

Sincerely,

 

/s/ Prashant Kohli

 

Prashant Kohli

Chief Executive Officer

 

 

 

 

I have read, understand and accept these terms and conditions of employment. I further understand that while my salary, benefits, job title and job duties may change from time to time without a written modification of this agreement, the at-will term of my employment is a term of employment which cannot be altered or modified except in writing, signed by me and Acasti’s CEO. By accepting this offer, I confirm that I am able to accept this job and carry out the work involved without breaching any legal restrictions on my activities, such as restrictions imposed by a current or former employer.

 

/s/ Robert J. DelAversano 11/21/2023

 

Signature Date

 

 


GRAPHIC 3 img95305537_0.jpg GRAPHIC begin 644 img95305537_0.jpg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acst-20240105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 5 acst-20240105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 acst-20240105.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Jan. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 05, 2024
Entity Registrant Name ACASTI PHARMA INC.
Entity Central Index Key 0001444192
Entity Emerging Growth Company false
Entity File Number 001-35776
Entity Incorporation, State or Country Code A8
Entity Tax Identification Number 98-1359336
Entity Address, Address Line One 103 Carnegie Center
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 649-9272
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol ACST
Security Exchange Name NASDAQ
XML 8 acst-20240105_htm.xml IDEA: XBRL DOCUMENT 0001444192 2024-01-05 2024-01-05 false 0001444192 8-K 2024-01-05 ACASTI PHARMA INC. A8 001-35776 98-1359336 103 Carnegie Center Suite 300 Princeton NJ 08540 609 649-9272 false false false false Common Shares, no par value per share ACST NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports acst-20240105.htm acst-20240105.xsd acst-20240105_lab.xml acst-20240105_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "acst-20240105.htm": { "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20240105", "dts": { "inline": { "local": [ "acst-20240105.htm" ] }, "schema": { "local": [ "acst-20240105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "acst-20240105_lab.xml" ] }, "presentationLink": { "local": [ "acst-20240105_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_6c80e3a2-2bba-4544-b53f-0b04c6917063", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20240105.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6c80e3a2-2bba-4544-b53f-0b04c6917063", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20240105.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acastipharma.com/20240105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-24-002689-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-002689-xbrl.zip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end